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Abstract: Retinoic acid (RA) agents possess anti-tumor activity through their ability to induce cellular
differentiation. However, retinoids have not yet been translated into effective systemic treatments
for most solid tumors. RA signaling is mediated by the following two nuclear retinoic receptor
subtypes: the retinoic acid receptor (RAR) and the retinoic X receptor (RXR), and their isoforms.
The identification of mutations in retinoid receptors and other RA signaling pathway genes in human
cancers offers opportunities for target discovery, drug design, and personalized medicine for distinct
molecular retinoid subtypes. For example, chromosomal translocation involving RARA occurs in
acute promyelocytic leukemia (APL), and all-trans retinoic acid (ATRA) is a highly effective and even
curative therapeutic for APL patients. Thus, retinoid-based target discovery presents an important
line of attack toward designing new, more effective strategies for treating other cancer types. Here,
we review retinoid signaling, provide an update on retinoid agents and the current clinical research
on retinoids in cancer, and discuss how the retinoid pathway genotype affects the ability of retinoid
agents to inhibit the growth of colorectal cancer (CRC) cells. We also deliberate on why retinoid
agents have not shown clinical efficacy against solid tumors and discuss alternative strategies that
could overcome the lack of efficacy.
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1. Introduction
Our goal herein is to review the current research findings on retinoic acid (RA) agents,
and to provide an update on clinical studies that use retinoids against cancers. We will
firstly briefly discuss the function of the retinoid signaling pathway. Then, we will provide
a discussion of retinoid drug structure, mechanism of action, and pharmacokinetics. Finally,
we will discuss how the retinoid pathway genotype affects the ability of retinoid agents
to inhibit the growth of colorectal cancer (CRC) cells. For example, given that different
RA ligands have different affinities for the various RA receptor subtypes, it provides
new strategies for designing molecular treatment approaches using select retinoid agents
against cancers that carry mutations in specific RA receptor types. The overall focus of this
paper is to understand how the identification of mutations in RA receptors and other RA
signaling pathway genes in human cancers offers opportunities for target discovery, drug
design, and personalized medicine, for distinct molecular retinoid subtypes. Moreover, we
will make the case that recognizing why retinoid agents have not shown clinical efficacy
against solid tumors provides insight into how to design alternative approaches that could
overcome the lack of anti-cancer efficacy of retinoids.
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2. Background
Retinoic acid (RA) is an active metabolite of vitamin A. It regulates a network of
genes that are involved in embryonic development, cell growth, differentiation, tissue
homeostasis, and apoptosis. Vitamin A is derived from plants and animals, and it has
important functions in the human body. Mammals are able to synthesize vitamin A, which
is obtained from beta-carotene-like colored fruit and vegetables, or animal sources, such
as eggs and butter [1]. Retinoids are a family of signaling molecules, derived from retinol
(vitamin A). In the body, retinoids are stored as retinyl esters in hepatic stellate cells [2].
They play a role in cellular differentiation, growth, and apoptosis [3]. Retinoids consist
of a cyclic hydrophobic end group, a polyene or conjugated side chain, and a polar end
group. Retinoids are small molecules, which allow them to enter cells through the plasma
membrane. Retinoids are irreversibly oxidized to their naturally occurring RA derivatives
(Figures 1 and 2), which include all-trans retinoic acid (ATRA), 9-cis-retinoic acid (9-cis
RA), and 13-cis-retinoic acid (13-cis RA). Synthetic retinoids, such as bexarotene [4] and
fenretinide [5], are other available agents.

Figure 1. Chemical structure of physiological retinoids. The basic structure of the retinoid molecules
consists of a cyclic end group, a polyene side chain and a polar end group. The conjugated system is
formed by alternating C=C double bonds in the polyene side chain.

Retinoic acid has been shown to be a chemotherapeutic agent in the treatment of
acute promyelocytic leukemia (APL). RA therapy has also been shown to improve the
survival of neuroblastoma patients [6]. Using retinoids to treat other cancers has shown
limited success. Nonetheless, the success of RA against APL has led to many investigations,
to elucidate how RA signaling becomes dysregulated in cancer cells. For example, the
mechanism underlying the ability of ATRA to induce differentiation of APL cells has been
studied to understand how RA agents might be used for the differentiation of other cancer
cell types. Indeed, preclinical studies show that 9-cis RA is useful in the prevention of
prostate and breast cancer [7,8]. Moreover, 13-cis RA has shown clinical promise in patients
with neuroblastoma and thyroid cancer [9]. The evidence for the activity of RA against
other tumor types is much weaker. Information on retinoid signaling and different retinoid
agents, as well as preclinical and clinical studies of RA and its dysregulation in various
solid tumor types, bear further discussion (see below).
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Figure 2. This figure illustrates the RA signaling pathway which plays a role in tissue homeostasis.
Retinol, travels through the bloodstream bound to retinol-binding protein (RBP) and transthyretin
(TTR). An integral plasma membrane protein, stimulated by retinoic acid 6 (STRA6), allows cellular
uptake of retinol across the cell membrane into the target cell cytoplasm. Inside the cell, retinol binds
to cellular retinol-binding protein (CRBP), which delivers it to the enzymes that convert it to ATRA
in two steps. First, retinol is reversibly oxidized into retinal by cytosolic alcohol dehydrogenase or
retinol dehydrogenase (ADH/RDH) or short-chain dehydrogenase/reductases (SDRs, not shown).
Next, retinal is irreversibly converted to retinoic acid or all-trans retinoic acid by the aldehyde
dehydrogenase (ALDH) enzyme family members. ATRA either gets degraded by ATRA-degrading
cytochrome P450 reductases, such as CYP26A1, which converts ATRA to inactive metabolites, or it
binds to cellular retinoic acid-binding proteins (CRABPs) and gets transported into the nucleus. Once
inside the nucleus, ATRA functions as a ligand and binds to a heterodimer of retinoic acid receptor
(RAR) and retinoid X receptor (RXR). The RAR/RXR heterodimer binds to retinoic acid response
elements (RAREs) in the regulatory region of target genes, which triggers a conformational change
by inducing the release of co-repressors and the recruitment of co-activator complexes.

3. Retinoic Acid Signaling in Normal Cells
Retinoic acid is an active biological metabolite of vitamin A or all-trans retinol. RA and
its related analogues (retinoids) regulate networks of genes that are involved in embryonic
development, cell growth, differentiation, homeostasis, and apoptosis [10,11]. RA signaling
(Figure 2) is mediated by the formation of a heterodimer, involving the following two
retinoid receptor subtypes: retinoic acid receptor (RAR) and retinoic X receptor (RXR).
3.1. Retinoic Acid Receptors
The RARs and RXRs are members of a nuclear receptor family. Specifically, they are
members of the ligand-dependent transcription factor family of steroid/thyroid/nuclear
receptors [11–14]. Each receptor subtype has different isoforms. RARA and RARG have
two isoforms, RARA1, RARG1, RARA2, RARG2, and RARB has five isoforms, RARB1-4
and B10 . All the subtypes of RXR have two isoforms, one and two [1,15]. The different
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receptor subtype genes are subjected to differential splicing and alternative promoters,
which generate isoforms with distinct regulatory and functional properties [16].
The receptors are contained within the cytoplasm and sub-nuclear compartments, where
they bind to RA and activate signaling through the formation of dimers, as reviewed in [17].
RAR interacts with RXR to form RAR/RXR heterodimers, which leads to the transcriptional
regulation of primary genes after binding to retinoic acid response elements (RAREs) [14].
RAREs are comprised of tandem 50 -AGGTCA-30 sites, known as the DR1–DR5 [18].
The receptors act as ligand-dependent transcription factors, which regulate the expression of primary target genes by specific binding to the RAREs on the promoter region of
DNA [11,13]. The ligand ATRA binds to, and activates, RARs, with high affinity; the ligand
9-cis RA binds to, and activates, RXRs more than RARs, and the ligand 13-cis RA binds
to, and activates, RARs. RARs are not only ligand-dependent transcriptional regulators,
but can also exhibit extra-nuclear non-transcriptional effects and lead to activating kinase
cascades within the nucleus [13]. RXRs form heterodimers with RARs, and can also form
homo- and hetero-dimers with other nuclear receptors [1,19]. Depending on the partner,
RXR can serve as a silent or active partner in the dimers. As a silent partner, RXR dimers
will not regulate RA signaling, in which case RXR functions as a main regulator [1]. In
the absence of a ligand, RAR/RXR heterodimers interact with a multiprotein complex
that contains transcription co-repressors, which induce histone deacetylation, chromatin
condensation, and transcription suppression [20]. In the presence of a ligand, the corepressor is displaced from the receptors and the co-activators are recruited with histone
acetyltransferases (HATs) activity, which leads to the activation of transcription [18,21].
3.2. Other Retinoid Signaling Components
The ability of RA to induce differentiation, cell cycle arrest, and apoptosis is also
mediated through other cellular components, such as cellular retinoic acid-binding protein
1 (CRABP1) and fatty acid-binding protein 5 (FABP5) [22,23]. For example, RA has an
enhanced apoptotic effect in cells that have a high CRABP1/FABP5 ratio. RA also binds
to orphan nuclear receptors, nuclear receptor peroxisome proliferator-activated receptors
(PPARB and PPARD), which increases the survival of cells that express high levels of
FABP5 [24]. The RAR/RXR heterodimer acts as a transcriptional repressor in the absence of
a ligand, and the RA receptors bind to DNA involving a co-repressor complex, nuclear corepressor (NCoR) and silencing mediator for retinoid and thyroid receptor (SMRT) proteins.
Both NcoR and SMRT form complexes with histone deacetylase (HDAC) [25,26]. The
binding of RA alters the interactions of RAR/RXR heterodimers with co-regulatory proteins,
and interacts with co-activator proteins with high affinity. Upon ligand binding, coactivator proteins bind to nuclear hormone receptors, to increase the transcriptional activity.
The co-activator proteins include the p160/steroid receptor co-activator (SRC) protein
family (SRC-1, SRC-2, SRC-3), with C-terminal domains that mediate the interaction with
HATs, and coregulators such as (CBP/P300) [27–29]. Gillespie et al. [30] investigated cell
lines that were mutated for the three different RARs, using chromatin immunoprecipitation
(ChIP) analysis. This study revealed that the recruitment of co-activators to the RAR/RXR
heterodimers occurs at specific RAREs sites. The binding of the RAR/RXR heterodimer to
RAREs, and recruitment of coactivators, leads to the transcription of retinoid target genes,
for further detail please see [30,31] (Figure 2).
4. Retinoid Agents
Below, we discuss the three known stereoisomers of RA, including all-trans retinoic
acid (tretinoin), 13-cis retinoic acid (isotretinoin), and a less-stable isomer, 9-cis retinoic
acid (alitretinoin). Other retinoid agents are inhibitors of the enzyme CYP26A1, which are
collectively termed RAMBAs (retinoic acid metabolism blocking agents). Below, we also
discuss the RAMBAs, liarozole and talarozole.
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4.1. All-Trans Retinoic Acid (ATRA or Tretinoin)
4.1.1. Mechanism of Action
All-trans retinoic acid is an active biological metabolite of vitamin A and has shown
remarkable activity as a treatment for acute promyelocytic leukemia (APL) [32]. Classically,
ATRA is a prime example of a cyto-differentiating agent that exerts its activity as an antitumor drug [33]. The pharmacological activity of ATRA is mediated through binding to
RARA receptors [14,21]. It binds RARs with high affinity, but does not bind RXRs [34].
ATRA can be converted non-enzymatically to stereoisomers (9-cis RA and 13-cis RA) [35].
The mechanism of action (MOA) of ATRA is not fully clarified. However, the MOA
following treatment of APL involves three processes. First, the restoration of the normal
structure of the nuclear bodies, and the elimination of the PML–RARA protein via caspasemediated cleavage and proteasome-dependent degradation. Second, the conversion of
PML–RARA from a repressor to an activator. Third, the induction of gene expression
by ATRA, which leads to differentiation [36]. Overall, ATRA induces differentiation of
APL cells, because of its ability to promote PML–RARA degradation and dissociation of
co-repressors [37].
4.1.2. Pharmacological Uses
Due to the promising results of ATRA in the treatment of APL, several studies have been
conducted to determine the effects of ATRA in the treatment of other diseases and cancers.
In a recent study, Xiao-Jie Chen et al. investigated the effect of ATRA on cell proliferation,
cell cycling, apoptosis, and PD-L1 (programmed death receptor ligand-1) expression in oral
squamous cell carcinoma (OSCC) and oral dysplasia (OD) [38]. The study showed that ATRA
induces anti-tumor effects by downregulating STAT3 expression, and subsequent signaling
in OSCC and OD. The downregulation of STAT3 by ATRA caused inhibition of proliferation,
induction of apoptosis, and downregulation of PD-L1 expression. The observed effects indicate
that ATRA is a potential therapeutic agent against OSCC and OD [38].
In the case of breast neoplasms, ATRA induces re-differentiation of early transformed
breast epithelial cells. A model of breast cancer progression was developed, by treating
human normal-like breast epithelial cell lines with estradiol. While the cells at an advanced
stage of progression did not show morphological changes following ATRA treatment,
ATRA was able to re-differentiate the transformed cells at early stages of neoplastic progression, to a normal-appearing morphology. This finding suggests that ATRA may potentially
be useful as a chemo-preventive agent, to prevent the progression of premalignant lesions
of the breast [39]. As a differentiating agent, ATRA was found to inhibit cell proliferation,
sphere formation, decrease stem cell (SC) population size, SC proliferation, and increase
SC differentiation in ALDH+ colon cancer SCs [40]. Anti-tumor effects of ATRA were also
observed in a study by Ming-Jer Young et al., whereby ATRA downregulated ALDH1 cancer SC (CSC) marker expression, and inhibited tumor formation in ovarian cancer cells [41].
The study confirms that ALDH1 is a CSC marker, and it regulates tumor formation in
ovarian cancer cells through the downstream signaling of FoxM1/Notch1. Furthermore,
ATRA downregulates ALDH1/FoxM1/Notch1 by targeting self-renewal pathways, and by
suppressing sphere formation, cell migration, invasion of cells, and tumorigenesis [41].
4.2. 13-cis Retinoic Acid (Isotretinoin)
4.2.1. Mechanism of Action
The 13-cis retinoic acid is a naturally occurring retinoid. Its use was first approved
in 1982 as an oral treatment for severe acne, by the US Food and Drug Administration. It
remains the only clinically effective therapy that is able to induce prolonged remission
and significant improvement in acne patients [42,43]. The use of 13-cis RA has also been
established as a treatment for children with high-risk neuroblastoma [44]. In neuroblastoma
cell lines, 13-cis RA (Figure 1) has a longer half-life and higher, consistent peak plasma
levels compared to other RA isomers. When administered orally, plasma concentrations
peak between 2 and 4 h, and show an eliminated half-life of 10–20 h [45]. Also, 13-cis
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RA has different pharmacokinetic properties than ATRA and 9-cis-RA do [46], and is
considered to be a storage form of biological active ATRA and 9-cis RA [47]. Further, 13cis-RA does not demonstrate specific binding to RXRs and CRABPs, and it has a 100-fold
lower binding affinity to RARs [48]. It can be converted intracellularly to metabolites, and
act as a pro drug that is an agonist for RAR and RXR nuclear receptors [42,49]. Moreover,
13-cis RA is not active in transactivation assays, in the way that ATRA and 9-cis RA are,
and this led to the general belief that it is not a key molecule in the regulation of gene
transcription. The mechanism of action of 13-cis RA is unknown, but there are several
possible mechanisms that explain the effects of 13-cis RA. First is the isomerization of 13-cis
RA to ATRA [50]. The 13-cis RA may also regulate gene expression by binding to, as of yet,
an unidentified nuclear receptor in an RAR–RXR independent pathway [51]. Second, 13-cis
RA may be enzymatically isomerized, first to ATRA, and then to 9-cis RA [51]. So, 13-cis
RA may be exerting its effects by regulating target gene transcription through ATRA or
9-cis RA [52,53]. Third, 13-cis RA may enhance cellular function by increasing target gene
mRNA or its protein stability [54]. Fourth, 13-cis RA could be non-enzymatically produced
by spontaneous isomerization from ATRA or 9-cis RA [52].
4.2.2. Pharmacological Uses
A study by Matthay et al. investigated clinical outcomes in high-risk neuroblastoma
pediatric patients, who were treated with chemotherapy, radiotherapy, transplantation,
and 13-cis RA [55]. The response to treatment with 13-cis RA suggested that this retinoid
was clinically beneficial for patients with improved outcomes, without progressive disease.
This study suggested that while 13-cis RA was not effective in patients with high residual
disease burden, it was effective in patients with the least residual disease, and was most
effective in those that had a complete response [55].
In toxicity studies using animal models, the treatment of mice with 13-cis RA was
associated with neurological effects, such as increased depression-related behavior, and
impairment in spatial learning and memory [54]. These mood and behavior alterations
were attributed to altered CNS function, from decreased hippocampal neurogenesis [56,57].
The effect on depression-related behaviors was not immediate, but required several weeks.
Thus, any effect of 13-cis RA on gene expression must be a secondary effect accumulating
over time, and not a direct, immediate influence on gene expression [58]. Fortunately,
in humans, epidemiological studies have not reported a link between 13-cis RA use and
clinical depression in patients.
An interesting study by Nelson et al. showed that 13-cis RA induced apoptosis and
cell cycle arrest in human SEB-1 sebocytes by an RAR-independent mechanism [59]. The
study evaluated the effects of ATRA, 9-cis RA, and 13-cis RA on the apoptosis, cell cycling,
and proliferation in SEB-1 sebocytes and keratinocytes. Further, 13-cis RA produced greater
effects at 48 and 72 h, in inducing apoptosis and inhibiting growth in sebocytes, compared
to the other agents. The effects are attributed to the efficacy of 13-cis RA in reducing the
production of sebum [59]. Thus, the induction of apoptosis appears to be the primary
mechanism that explains the pharmacological mode of action and adverse effects of 13-cis
RA in the treatment of neuroblastoma, APL, and severe acne [60].
4.3. 9-cis Retinoic Acid (Alitretinoin)
4.3.1. Mechanism of Action
The 9-cis retinoic acid is an isomer of ATRA, but differs from ATRA due to its ability
to activate both RAR and RXR. Unlike ATRA, which does not bind RXR, 9-cis RA is a highaffinity ligand for RXR. The activation of RXR by 9-cis RA allows for heterodimerization
with RARs, peroxisome proliferator activator receptor (PPAR), thyroid hormone receptor
(TR), vitamin D receptor (VDR), farnesoid receptor (FXR), pregnane X receptor (PXR), and
constitutively activated receptor (CAR) [61]. Also, 9-cis RA can induce RXR homodimer
formation, which elicits a response allowing for the activation of PPAR target genes. A
study by Lin, Y. W et al. showed that 9-cis RA not only functions by regulating nuclear gene
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transcription, but it also regulates RXR in mitochondria, to activate mitochondrial gene
transcription [62]. Moreover, 9-cis RA (0.1% gel) is approved by the FDA as a treatment
for Kaposi’s sarcoma. Oral administration of 9-cis RA can be variably absorbed, but it is
enhanced after food intake. The half-life is 2–10 h, and elimination occurs via excretion [63].
4.3.2. Pharmacological Uses
A study by Yang et al. examined the effects of 9-cis RA on the growth and apoptosis of
cutaneous T-cell lymphoma (CTCL) cells. The treatment of CTCL cells (HUT78, Myla) with
9-cis RA inhibited proliferation in both the cell lines and induced apoptosis. Furthermore,
9-cis RA treatment of these cell lines led to increased RARA, as well as increased RARG
and RXRA retinoid receptor expression [64]. A preclinical study by Seong-Jin Yu indicated
that 9-cis RA can induce neurological repair in the brains of adult male rats after stroke. To
examine the neuro-reparative role of 9-cis RA in rats with stroke, 9-cis RA was administered
intranasally, which induced repair of the brain and enhanced recovery of motor function.
Thus, the authors concluded that 9-cis RA may offer a non-invasive treatment approach to
patients with stroke [65].
4.4. Liarozole (R75251)
4.4.1. Mechanism of Action
Liarozole is a derivative of imidazole and has two main mechanisms of action. First, it
is an RA metabolism blocking agent (RAMBA) that inhibits the cytochrome P-450-mediated
catabolism of RA [66]. The inhibition of the P-450 enzyme CYP26A1 leads to increased
tissue and plasma levels of endogenous RA [67]. Second, it is an effective aromatase
inhibitor [68,69].
4.4.2. Pharmacological Uses
A study by Gilden Melissa et al. evaluated the influence of liarozole on the proliferation of leiomyoma fibrosis cells and the expression of extracellular matrix (ECM)
components in immortalized leiomyoma cells [70]. The study showed that liarozole significantly decreased proliferation and ECM gene expression in leiomyoma cells [70]. Different
doses of liarozole have been used in various studies, ranging from 50 mg to 300 mg. A
multi-centered, double-blinded, placebo-controlled, dose-ranging study by Berth-Jones
et al. determined the lowest effective oral dose of liarozole in the treatment of severe
psoriasis vulgaris. A twice daily dose at 75 mg was the lowest effective dose [71]. The
study also showed that oral liarozole is well-tolerated and provides an effective treatment
for psoriasis.
Three phase II studies by P E Goss et al. were conducted to determine the efficacy and tolerability of liarozole in the treatment of estrogen receptor-negative (ER-), tamoxifen-refractory
or chemotherapy-resistant postmenopausal metastatic breast cancer. Patient cohorts included
ER-negative (group 1), ER-positive or unknown disease tamoxifen-refractory (group 2), ERpositive, and ER-negative chemotherapy-resistant (group 3) patients. The patients received
oral doses (150–300 mg) of liarozole twice daily. The results showed that 25% of the patients in
groups 1 and 2, and 11% of the patients in group 3 responded to the treatment. There was an
87% decrease in plasma estradiol levels after one month of treatment. The study results [72]
also confirmed liarozole’s mechanism of action as a RAMBA.
Another study by Verfaille et al. investigated the efficacy, safety, and tolerability of
oral liarozole versus the second generation monoaromatic retinoid acitretin (etretin) in
the treatment of patients with ichthyosis [73]. In this phase II/III study, the patients were
randomized to receive either 75 mg of liarozole in the morning and evening (total 150 mg),
or 10 mg of acitretin in the morning and 25 mg of acitretin in the evening (total 35 mg). The
authors observed mild-to-moderate RA-related adverse effects in both the groups, but side
effects occurred less frequently in the group that was treated with liarozole. Although this
study shows that liarozole for ichthyosis is as effective as the retinoid acitretin, liarozole
has better tolerability [73].
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4.5. Talarozole (R115866)
4.5.1. Mechanism of Action
Talarozole is another RAMBA that specifically inhibits CYP26 enzyme activity [69].
It increases endogenous RA in the plasma and skin, and exerts similar effects as those
described for retinoids. Nanomolar concentrations of talarozole affect RA catabolism, and
other CYPs are inhibited by micromolar concentrations. Talarozole is a more effective
inhibitor of CYP26 (IC50 = 4 nM) compared to liarozole (IC50 = 3 uM) [74]. Moreover,
talarozole has a greater specificity for CYP26 as compared to liarozole, with >300-fold higher
IC50 values for CYP19, CYP17, CYP2C11, CYP3A, and CYP2A1 than for CYP26A1 [69].
4.5.2. Pharmacological Uses
The pharmacological characterization of talarozole was reported in an animal study
by Stoppie, et al. The rats were treated with a single dose of talarozole (2.5 mg/kg), which
led to a significant increase in endogenous RA levels in the plasma, skin, fat, kidney,
and spleen [74]. The RA levels returned to baseline after 18 h following administration.
Treatment with talarozole showed typical retinoid side effects, which include a decrease in
vaginal keratinization, induced pinnal hyperplasia, conversion of caudal para to orthokeratosis, and up-regulation of hepatic CYP26 expression in rats [74]. The effects of talarozole
were studied in combination with ATRA on cultured human epidermal keratinocytes.
Giltaire, S et al. showed that talarozole potentiates the effects of ATRA [75]. An effect
from talarozole was not observed in the absence of ATRA. However, when talarozole was
combined with low concentrations of ATRA, the effect of ATRA was potentiated. The
effect was evident by the increased expression of HB-EGF and involucrin, and a decrease
in keratin 10 expression [75].
In an open-label, single-arm trial, patients with moderate to severe plaque-type psoriasis
were treated with talarozole (1 mg/day) for eight weeks, to assess efficacy, safety, and tolerability. The treatment resulted in a significant reduction in psoriasis, as measured by the severity
index (PASI), with additional improvement seen even after the follow-up period. Orally
administered talarozole appears to be well-tolerated, but further evaluation of efficacy and
safety is ongoing [76]. For example, Verfaille et al. also confirmed the efficacy and tolerability
of talarozole (1 mg/day for 12 weeks) in male patients with moderate-to-severe facial acne
vulgaris [77]. While numerous studies have evaluated the anti-tumor effect of liarozole and
another RAMBA, ketoconazole, the potentiality of talarozole as an anti-tumor agent has not
yet been explored, indicating the need for further investigation.
5. Effect of Retinoids in the Chemoprevention and Treatment of Various Cancers
There have been a number of clinical trials conducted on solid tumors, using retinoids,
which we have listed in Table 1. Below, we discuss select preclinical studies and clinical
trials that have been conducted in different tumor types.
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Table 1. Clinical trial table.
Drug

Completed Clinical Trials

Current/Recruiting Clinical Trials

Effect of all-trans retinoic acid
with chemotherapy-based
paclitaxel and cisplatin as
first-line treatment of patients
with advanced non-small-cell
lung cancer

NCT01048645

All-trans retinoic acid, and arsenic
+/− idarubicin

NCT00413166

A trial of all-trans retinoic acid
(ATRA) in advanced adenoid
cystic carcinoma

NCT03999684
All-trans retinoic acid (ATRA) in the
treatment of recurrent/metastatic
adenoid cystic carcinoma of the head
and neck (Aplus)

All-Trans retinoic acid

CT.Gov
Identifier/Ref

NCT04433169

All-trans retinoic acid in
combination with standard
induction and consolidation
therapy in older patients with
newly diagnosed acute myeloid
leukemia

NCT00151255

To immunize patients with
extensive stage SCLC combined
with chemotherapy with or
without all-trans retinoic acid

NCT00617409

ATRA Trial—activity of ATRA in
combination with anastrozole in
pre-operative phase of operable
HR-positive/HER2-negative early
breast cancer eBC ATRA trial

NCT04113863

Effect of all-trans retinoic acid
with chemotherapy based on
paclitaxel and cisplatin as first
line treatment of patients with
advanced non-small-cell lung
cancer

NCT01048645

All-trans retinoic acid in
combination with standard
induction and consolidation
therapy in older patients with
newly diagnosed acute myeloid
leukemia

NCT00151255

Study of dasatinib and all-trans
retinoic acid for
relapsed/refractory and/or
elderly patients with acute
myelogenous leukemia (AML) or
myelodysplastic syndrome

NCT00892190

Oral arsenic trioxide for newly
diagnosed acute promyelocytic
leukemia

NCT03624270
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Table 1. Cont.
Drug

9-Cis retinoic acid

13-Cis retinoic acid

Completed Clinical Trials

Current/Recruiting Clinical Trials

CT.Gov
Identifier/Ref

The pharmacokinetics of a single
dose of 9-cis retinoic acid
(alitretinoin, tocino) in patients
with moderate-to-severe hepatic
insufficiency

NCT01261923

Alitretinoin in the treatment of
chronic hand eczema

NCT00519675

Single dose of 9-cis retinoic acid
in hepatic patients

NCT01891526

Efficacy of alitretinoin treatment
in patients with pustular form of
psoriasis

NCT01245140

A phase I trial of tamoxifen and
9-cis retinoic acid in breast cancer
patients

NCT00001504

A study of ALRT1057 in patients
with AIDS-related Kaposi’s
sarcoma

NCT00002188

Identifying the genetic predictors
of severe acne vulgaris and the
outcome of oral isotretinoin
treatment (SA)

NCT01727440

13-cis retinoic acid with or
without Vitamin E for prevention
of lung cancer (13-Cis)

NCT00002586

RA-4: 13-cis retinoic acid for
treatment of men with
azoospermia

NCT03323801

Oral liquid 13-cis retinoic acid
(13-CRA)

NCT03291080

Double-blind phase III trial of
effects of low-dose 13-cis retinoic
acid on prevention of second
primaries in stages I–II head and
neck cancer

NCT03370367

Belinostat and isotretinoin in
treating patients with solid
tumors that are metastatic or that
cannot be removed by surgery

NCT00334789

Isotretinoin in preventing skin
cancer

NCT00025012

Safety and effectiveness of giving
isotretinoin to HIV-infected
women to treat cervical tumors

NCT00001073

Interferon alfa, isotretinoin, and
paclitaxel in treating patients with
recurrent small-cell lung cancer

NCT00062010
Cabozantinib in combination with
13-cis retinoic acid in children with
relapsed or refractory solid tumors.

NCT03611595
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Table 1. Cont.
Drug

Completed Clinical Trials

Current/Recruiting Clinical Trials

CT.Gov
Identifier/Ref

High-dose 3F8/GM
immunotherapy plus 13-cis
retinoic acid for consolidation of
first remission after myeloablative
therapy and autologous stem cell
transplantation

NCT01183416

Isotretinoin plus interferon in
treating patients with recurrent
cancer

NCT00002506

3F8/GM-CSF immunotherapy
plus 13-cis retinoic acid for
consolidation of first remission
after non-myeloablative therapy
in patients with high-risk
neuroblastoma

NCT01183429

Vorinostat and isotretinoin in
treating patients with high-risk
refractory or recurrent
neuroblastoma

NCT01208454

3F8/GM-CSF immunotherapy
plus 13-cis retinoic acid for
primary refractory neuroblastoma
in bone marrow

NCT01183897

Liarozole

A randomized, double-blind,
placebo-controlled phase II/III
trial to evaluate the efficacy and
safety of 2 doses of oral liarozole
(75 mg od, and 150 mg od) given
during 12 weeks in lamellar
ichthyosis

NCT00282724

Talarozole

None

5.1. Retinoids and Acute Promyelocytic Leukemia (APL)
Pharmacological doses of retinoids are useful in the treatment of some cancer types,
and able to restore a normal response in the differentiation of tumor cells. A classic example
is the use of ATRA in the treatment of APL, which is the most efficacious use of RA in cancer
therapy since the mid-1980s. In 1995, the United States Food and Drug Administration
approved the use of oral ATRA in patients with APL, following a report on the potentiality
of ATRA to induce in vitro differentiation of APL cells and provide a therapeutic tool in
the treatment of acute myeloid leukemia (AML) [78]. To date, the oral administration of
ATRA is still considered a standard therapy in the treatment of APL. Moreover, APL is
the only type of cancer that can reach 95% remission with ATRA and chemotherapy [79].
Studies have shown that most APL cases have a chromosome translocation involving
chimeric fusion of promyelocytic leukemia genes and the RARA gene. The PML–RARA
fusion protein acts as a transcriptional repressor that blocks physiological RA-mediated
differentiation of hematologic precursors, which leads to the accumulation of granulocyte
precursor promyelocytes [80]. In the treatment of APL, ATRA binds the RARA aspect
of the fusion protein that leads to the dissociation of the co-repressors, which induces
differentiation and complete remission in 95% of patients [81,82].
The combination of arsenic trioxide with ATRA has further improved the efficacy of
treatment for APL. Arsenic trioxide binds to the PML aspect of the fusion protein and can
even lead to a relatively high cure rate, as a single agent in APL patients [79,83]. Studies also
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show that the combined use of ATRA and arsenic trioxide act synergistically to enhance
apoptosis and/or differentiation, depending on the dose [84]. The successful use of ATRA
in the treatment of APL has led to efforts to test natural retinoids in the treatment of other
cancers. Unfortunately, the therapeutic and chemo-preventive benefits of retinoids in solid
tumors remain uncertain.
5.2. Retinoids and Breast Cancer
The first preclinical analyses of RA on breast cancer were done using cell lines, which
dates back to the late 1970s. In these early preclinical studies, three of the breast cancer cell
lines, Hs578T, 734B, SK-BR-3, showed growth inhibition, as follows: 27%, 50% and 83%,
respectively. However, the MDA-MB-157 and Hs578Bst cell lines were not affected [85].
Fenretinide, a synthetic analog of retinoids, has also been studied in breast cancer prevention trials. An eight-year clinical study of fenretinide and breast cancer patients revealed
no significant difference in the reduction in contralateral and ipsilateral breast cancer [86].
Some findings suggest that the RA receptor RARA and the estrogen receptor ER∝ target
common genes throughout the genome, to antagonistically regulate the genes that are associated with breast cancer [87]. Consequently, a clinical trial was conducted to investigate
the effect of adding hormonal therapy with retinoids in post-menopausal patients with
advanced breast cancer. The efficacy of 13-cis-RA vs. interferon alpha2 (IFN ∝ 2) with
tamoxifen, showed no significant difference in the overall survival after eight years [88]. A
phase II trial, performed by Bryan et al., investigated the drug combination of ATRA and
paclitaxel in patients with recurrent or metastatic breast cancer, which revealed an overall
clinical benefit of 76.4%. While the results appeared promising, the time to progression
and survival rates were similar to those reported for paclitaxel alone. However, an ability
of ATRA to induce differentiation and cell cycle arrest was evident, as increased stable
disease was observed [89].
5.3. Retinoids and Prostate Cancer
For prostate cancer (Pca) patients, hormonal agents are typically used to treat recurrent
disease following prostatectomy or radiotherapy, and for metastatic disease, but tumors
often become hormone refractory [90]. The use of fenretinide as a single agent therapy
in hormone refractory Pca patients with rising prostate-specific antigen (PSA), did not
show a reduction in PSA, suggesting a need for drug combination-based studies [91]. For
example, a randomized phase II study by Ferrari et al., involving patients with androgendependent prostate cancer, evaluated 13-cis RA in addition to hormonal therapy. The
results showed that 13-cis RA did not lead to a decline in PSA, nor did it reduce hormonal
therapy toxicity. Additionally, the antitumor activity of the drug combination was not
superior to the standard hormonal treatment [92]. Although one study found that a loss of
RXRA contributes to the tumorigenesis of prostate cancer [93], to date there are no clinical
trials that provide convincing evidence for the effectiveness of retinoids in prostate cancer.
5.4. Retinoids and Lung Cancer
A number of studies have been conducted to investigate the role of single-agent
retinoids in patients at high risk for developing lung cancer, and those with a history of
lung cancer. Early preclinical analyses on the effects of ATRA on human lung cancer cell
lines showed that 17 of 22 human small-cell lung cancer (SCLC) cell lines, and 9 of 15
non-small-cell lung cancer (NSCLC) cell lines, were resistant to retinoids. Two NSCLC cell
lines even showed growth stimulation following treatment with ATRA [94]. A randomized
phase II study by Arrieta Oscar et al. evaluated the combination ATRA, with paclitaxel
and cisplatin, in advanced NSCLC patients. The median progression-free survival (PFS)
rate and response rate (RR) favored the incorporation of ATRA in patients, as indicated by
the clinical outcome measures (RR—55.8% compared to 25.4%; PFS—8.9 months compared
to 6 months) and acceptable toxicity [95]. A phase III study assessed the addition of
bexarotene, a synthetic form of vitamin A, in first-line treatment with carboplatin and
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paclitaxel for NSCLC patients; however, there was no improvement in patient survival.
Although, the occurrence of high-grade hypertriglyceridemia in bexarotene-treated patients
correlated strongly with increased survival suggesting it may still hold some benefit in
first-line treatment for NSCLC patients [96]. A meta-analysis looking at the use of naturally
occurring retinoids in the treatment of lung cancer showed a lack of benefit; however,
bexarotene may still hold promise for select patients [97]. Overall, these studies have not
shown a clear benefit for use of retinoids in lung cancer.
5.5. Retinoids and Colorectal Cancer (CRC)
As discussed above, there have been a number of clinical trials conducted on solid tumors using retinoids, but we did not find any clinical trials listed on www.clinicaltrials.gov
involving the treatment of CRCs with retinoid agents. However, a number of preclinical
studies have been conducted on retinoids for CRC (discussed below), and the reader is also
referred to a recent review on the subject [17].
5.6. Chemoprevention of Cancer Using Retinoids
Various studies have also been conducted to evaluate the chemo-preventive potential
of retinoids as single agents, and in combination drug regimens with other chemotherapeutic agents. These studies were conducted on premalignant conditions, such as oral
leukoplakia, erythroplakia, xeroderma pigmentosum, bronchial metaplasia, laryngeal
papillomatosis, cervical dysplasia, actinic keratosis, and dysplastic nevi, as well as chemoprevention for second primary malignancies, such as esophageal, basal cell, breast, hepatocellular, squamous cell skin, cervical, and bladder carcinomas. The reader is referred to
several excellent reviews on the subject [98–103].
6. Retinoid Drugs Are Not Efficacious Against Solid Tumors—Why Not?
Retinoic acid (RA) agents possess anti-tumor activity through their ability to induce
cellular differentiation. Indeed, as discussed above, ATRA is a first-line treatment that cures
many acute promyelocytic leukemia (APL) patients, mainly due to ATRA’s ability to induce
the differentiation of APL cells into neutrophils [104–106]. Even though retinoids show
promising pre-clinical activity in human solid tumors, they have not yet been translated
into effective systemic treatments for most solid tumors. We believe that recognizing why
retinoid agents have not shown clinical efficacy against solid tumors could provide insight
into how to design alternative approaches that could overcome the lack of anti-cancer
efficacy of retinoids.
To explore this line of thinking, here, we provide a deliberation on studies that have
investigated the anti-cancer activity of retinoids in models of CRC [107–109], particularly
intestinal tumor development in the ApcMin/+ mouse model for familial adenomatous
polyposis (FAP) patients who carry germline APC mutations [110].
One of the first things we considered, which might explain the lack of retinoid efficacy
in colon tumors, was the presence of RA receptor mutations. Our search of RAR and
RXR mutations rates in CRC shows that, while mutations occur in all of the different RA
receptors, the mutation rate is quite low (<3%). The reader is directed to reference [17] to
get more information about the RA receptor mutations in CRC. There is other evidence
that the expression of some RA receptor genes (e.g., RARB) can be inactivated by DNA
hypermethylation [11]. Indeed, decreased RA receptor signaling has been shown to occur
in CRC [11,102,111]. Our bioinformatics investigation of the TCGA database [112] provides
additional information—it showed that RARA and RXRA receptor levels are prognostic
(p < 0.05) of CRC patient survival (Figure 3) [17]. Since RA receptor levels predict patient
survival, this suggests that RA receptors might play a role in tumor growth.
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Figure 3. Kaplan–Meier survival analysis of RA receptor gene expression (RARA—upper left panel, RARB—upper middle,
RARG—upper right, RXRA—lower left, RXRB—lower middle, RXRG—lower right) for their ability to predict CRC patient
survival (red = increased; blue = decreased) [17,106]. Our bioinformatics investigation of the TCGA database [112] showed
that RARA and RXRA retinoic acid receptor levels are predictive (p < 0.05) of CRC patient survival.

However, other factors are likely to play a role in drug resistance to retinoids. For
example, Volate et al. [107] showed that RA receptors, including Rara, Rarb, Rxrb, Rxrg, were
expressed in ApcMin/+ adenomas. Given the lack of receptor mutations in ApcMin/+ mice,
one would expect that ATRA should prevent adenoma formation in Min mice. However,
Mollersen et al. [113] tested ATRA in ApcMin/+ mice and found that ATRA treatment
failed to prevent tumor formation. Other studies were then conducted to discover which
mechanisms can explain this unexpected ATRA resistance in ApcMin/+ mice.
A key study by Shelton et al. [114] provided an important clue, by analyzing the
expression of CYP26A1, ATRA’s major catabolic enzyme. They found that CYP26A1
expression was increased in tumors from ApcMin/+ mice, and in tumors from FAP patients.
They also determined that CYP26A1 is a TCF4 target gene, which explains why CYP26A1
expression is increased due to upregulated WNT signaling in Apc-mutant tumor tissues.
Thus, an increase in CYP26A1, due to increased ATRA degradation, provides a mechanism
that explains the resistance of ApcMin/+ mice to ATRA treatment, and the failure of ATRA
to prevent tumor development.
A recent study by Penny et al. [110] provided more solutions to the problem. This
study involved treating ApcMin/+ mice with the CYP26A1 inhibitor liarozole. The administration of liarozole to ApcMin/+ mice increased endogenous RA signaling by blocking ATRA
metabolism, and dramatically reducing intestinal adenoma numbers in these Apc-mutant
mice. We also found that the treatment of human CRC cells with liarozole decreases
proliferation, sphere formation, and the size of the ALDH + SC population [115]. This
suggests that decreasing the intracellular metabolism of ATRA, by inhibiting CYP26A1
activity using liarozole, might be a way to increase ATRA levels and augment RA signaling
in tumor cells, including the reduction in tumor SC numbers in APC-mutant tissues.
These exciting results from pre-clinical studies raise the following important question:
“what is the frequency of APC mutation in human cancer?” As it turns out, APC is one
of the most frequently inactivated tumor suppressor genes across all solid tumor types
(Figure 4) [116,117]. While inactivation of APC in FAP and sporadic CRCs is due to APC
mutation, an often-unnoticed fact is that, in other cancers, APC inactivation often results from
the hypermethylation of APC’s promoter, and its epigenetic silencing. Thus, if CYP26A1 is a
TCF4 target gene that is upregulated by APC inactivation, it would increase ATRA degradation, lower intracellular ATRA levels, and diminish RA signaling. This provides a plausible
mechanism that explains why retinoid drugs are not efficacious against solid tumors.
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Figure 4. Frequency of APC inactivation in different human cancer types. Genomic tumor analyses
show that APC is one of the most frequently inactivated tumor suppressor genes across all solid
tumor types [116,117]. While inactivation of APC in FAP and sporadic CRCs is due to APC mutation,
in other cancers, APC inactivation often results from hyper-methylation of APC’s promoter and its
epigenetic silencing.

7. Pilot Study on the Effects of Retinoid Agents on APC-Mutant CRC Cells That Also
Carry RA Receptor Mutations
We then performed a pilot study to analyze APC-mutant CRC cell lines that have mutations in the RA receptor genes, to determine if cells that carry RA receptor mutations show
resistance to retinoid agents [118]. The results (Figure 5) show that HT29 cells, which only have
wild-type RA receptor, are sensitive to ATRA and 13-cis RA compared to SW480 cells that
have mutant RARA & RXRG, and HCT116 cells that have mutant RARA. LoVo cells, which
carry a mutation in RXRA, have also been shown to be resistant to retinoid treatment [108].
Interestingly, all three cell lines we analyzed showed the same dose response to the CYP26A1
inhibitor liarozole, indicating that the inhibition of ATRA metabolism that increases intracellular RA levels has the same effect on CRC cells regardless of whether they carry RA receptor
mutations. Another important aspect of this study was that all the CRC cells analyzed showed
some response to the growth-inhibitory effects of retinoids, even though the cells carry APC
mutations that would lead to WNT activation.
Indeed, the CRC cells with RA receptor mutations still showed growth inhibition
at higher doses of RA ligands, which indicates that these cells are still responsive to RA
signaling, but only if higher intracellular RA levels are achieved. Moreover, it shows that
RA receptor mutant cells show the same dose response to the CYP26A1 inhibitor liarozole
as non-mutant cells do; this indicates that the inhibition of CYP26A1 by liarozole leads to
a high enough intracellular RA level to induce growth inhibition. Thus, we predict that
liarozole and other RAMBAs will provide effective therapeutic approaches to target cancer
cells via RA signaling, and treatment with liarozole could overcome the lack of efficacy
that is traditionally seen in treating solid tumors with conventional retinoid agents.
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Figure 5. Effects of retinoid agents on CRC cells carrying RA receptor mutations. We investigated the effects of RA agents
on the growth and differentiation of various human colonic cell lines (HT29, SW-480 and HCT116) [118]. The cell lines
were plated, left to attach for 24 h, and serum starved for 24 h. The cells were treated for 24, 48 and 72 h with the various
retinoid agents. Cell proliferation was conducted using crystal violet assay. The upper panel gives the mutation status of
the CRC cell lines [17]. The middle panel shows the dose response curves for cell lines treated at 48 h. The lower panel
lists the IC50 (half-maximal inhibitory concentration) values for treated cell lines at 48 h. The data reveal that the ability of
various retinoid agents to induce differentiation of CSCs depends on the RA pathway genotype according to mutations in
RA signaling genes in CRC cells.

8. The CYP26A1 Inhibitor Liarozole Decreases CRC Cell Proliferation, Sphere
Formation, and Number of ALDH+ Cancer Stem Cells (CSCs)
Because the CYP26A1 inhibitor liarozole is able to decrease the proliferation of CRC
cells (discussed above), we also treated CRC cells with liarozole, to determine the effects
of CYP26A1 inhibition on sphere formation and SC numbers. We found that liarozole
decreased the number of colonospheres that formed in a dose-dependent manner. Also,
increasing doses of liarozole decreased the number of ALDH + CSCs [115]. Hence, our
results indicate that liarozole-induced inhibition of CYP26A1 leads to a decrease in cell
proliferation, SC self-renewal, and CSC numbers, by raising intracellular ATRA levels
in CRC cells. Moreover, our recent studies show that a link between WNT signaling
and retinoic acid signaling regulates colonic SCs, and human CRC evolves due to an
imbalance between WNT and RA signaling [119]. These findings could have broad clinical
significance, as most solid tumors are known to have the following: (i) SC overpopulation
that drives tumor development and growth, and (ii) inactivated APC that, by upregulating
CYP26A1 expression and increasing ATRA degradation [108], could induce resistance to
retinoids and reduce the effectiveness of retinoid therapies.
Other mechanisms that become altered due to APC mutations may also contribute to
the lack of efficacy of retinoid drugs against solid tumors. For instance, cancer growth is
usually sustained by the overexpression of proteins from the inhibitor of apoptosis protein
(IAP) family, such as survivin (BIRC5), which promotes cancer cell proliferation [120,121].
Indeed, survivin is highly overexpressed in many solid tumors, including lung, pancreatic,
breast, and colorectal cancers [122,123]. Survivin plays a role in promoting cell division
by activating aurora-B kinase, and inhibiting apoptosis by blocking caspase activation.
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Notably, we found that survivin is a TCF4 target gene. We observed that APC mutations
lead to the up-regulation of survivin expression in neoplastic intestinal tissues in mouse
and man [124,125]. We also reported, and others confirmed, that the expression of survivin
is downregulated by beta-catenin/TCF-4 signaling, which is normally controlled by wildtype APC [126–128]. Moreover, we have shown that the chemo-preventive agent sulindac
attenuates the expression of survivin in CRC cells [129]. Sulindac is a well-known nonsteroidal anti-inflammatory drug (NSAID), which is an FDA-approved chemo-preventive
agent that is used to inhibit adenoma development in FAP patients. We, and others, have
shown that sulindac also downregulates WNT signaling by inducing the degradation of
beta-catenin in CRC cells [129–134]. Thus, it is possible that the low efficacy of retinoid
agents in the treatment of solid tumors is due to survivin and other IAP proteins, which
become overexpressed due to APC mutations. Therapeutically overcoming the inhibition
of apoptosis in cancer may have important relevance to the development of retinoidbased therapies against solid tumors, because the addition of arsenic trioxide to ATRA in
the treatment of APL leads to synergistic effects by enhancing apoptosis [84]. Thus, the
development of ATRA-based regimens for treating other cancers will likely require drug
combinations that include agents such as apoptosis-inducing therapeutics.
9. Conclusions
The findings from our review of retinoids as chemo-preventive and molecular-targeted
anti-cancer therapies reveal that RA agents continue to hold promise as effective treatments
for human solid tumors. The results from the clinical trials discussed above, indicate that
strategies for designing retinoid-based anti-cancer therapies will likely need to incorporate
retinoids into drug combination regimens. For example, two studies [75,110] showed that
RAMBAs can potentiate the effect of ATRA. Moreover, our pilot study data indicate that
future therapeutic approaches will benefit, by genotyping tumors to determine the status
of RA signaling genes when administering RA-based treatments to oncology patients.
This is clearly exemplified by the efficacy of ATRA in APL patients whose malignant cells
have a chromosome translocation, involving chimeric fusion of promyelocytic leukemia
genes and the RARA gene. Other studies show that the RA receptor genotype is correlated
with the risk for cancer development, and to the response to retinoid chemoprevention
and therapy [101,135]. In this view, future research studies could also provide important
information by identifying which retinoid drugs are active against tumor cells that carry
specific mutations. For example, the preclinical studies discussed above suggest that
RAMBA agents may have selective activity against APC-mutant tumor tissues. Indeed,
the identification of mutations in RA receptors and other RA signaling pathway genes in
human cancers, offers tremendous opportunities for target discovery, drug design, and
personalized medicine for distinct molecular retinoid subtypes. Furthermore, continued
discovery of the mechanisms that explain how RA signaling regulates normal tissue homeostasis, and how the dysregulation of RA signaling in cancer drives tumor growth, should
provide valuable insight into how new retinoid-targeted therapies might be designed for
solid tumor patients.
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